Presence of high-risk HLA genotype is the most important individual risk factor for coeliac disease among at-risk relatives
- PMID: 34278595
- DOI: 10.1111/apt.16534
Presence of high-risk HLA genotype is the most important individual risk factor for coeliac disease among at-risk relatives
Abstract
Background: Family screening has been advocated as a means to reduce the major underdiagnosis of coeliac disease. However, the precise risk of the disease in relatives and the impact of patient- and relative-related individual factors remain obscure.
Aims: To investigate the individual risk of coeliac disease among patients' relatives.
Methods: Altogether 2943 relatives of 624 index patients were assessed for the presence of previous coeliac disease diagnosis, or were screened for the disease. Coeliac disease-associated human leucocyte antigen (HLA) genotype was determined from all participants. The association between individual factors and new screening positivity was assessed by logistic regression.
Results: There were 229 previously diagnosed non-index relatives with coeliac disease and 2714 non-affected (2067 first-degree, 647 more distant) relatives. Of these 2714 relatives, 129 (4.8%) were screening-positive (first-degree 5.1%, second-degree 3.6%, more distant 3.5%). The combined prevalence of the previously diagnosed and now detected cases in relatives was 12.2% (6.3% clinically detected, 5.9% screen-detected). In univariate analysis, age <18 years at diagnosis (odds ratio 1.60, 95% CI 1.04-2.45) in index, and age 41-60 years (1.73, 1.10-2.73), being a sibling (1.65, 1.06-2.59) and having the high-risk genotype (3.22, 2.01-5.15 DQ2.5/2.5 or DQ2.5/2.2 vs other risk alleles) in relatives were associated with screening positivity. Only high-risk HLA remained significant (2.94, 1.80-4.78) in multivariable analysis.
Conclusions: Unrecognised coeliac disease was common among at-risk relatives even in a country with an active case-finding policy, and also in relatives more distant than first-degree. The presence of a high-risk genotype was the most important predictor for screening positivity. ClinicalTrials.gov identifier NCT03136731.
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: coeliac disease-it's a family affair. Authors' reply.Aliment Pharmacol Ther. 2021 Oct;54(7):969. doi: 10.1111/apt.16584. Aliment Pharmacol Ther. 2021. PMID: 34506653 No abstract available.
-
Editorial: coeliac disease-it's a family affair.Aliment Pharmacol Ther. 2021 Oct;54(7):967-968. doi: 10.1111/apt.16552. Aliment Pharmacol Ther. 2021. PMID: 34506661 No abstract available.
References
REFERENCES
-
- Lindfors K, Ciacci C, Kurppa K, et al. Coeliac disease. Nat Rev Dis Primers. 2019;5:3.
-
- Dubé C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005;128:57-67.
-
- Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:823.e2-836.e2.
-
- Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26:1217-1225.
-
- Popp A, Kivelä L, Fuchs V, Kurppa K. Diagnosing celiac disease: Towards wide-scale screening and serology-based criteria? Gastroenterol Res Pract. 2019;2019:2916024.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials